Clearside Biomedical (CLSD) announced that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong. The article, which was published in December 2024 by Eye and Nature.com, provides a comprehensive overview of the intricate processes involved in clinical trial design and regulatory pathways for drug development, with a special focus on retinal diseases.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Highlights Advancements in Drug Delivery
- Clearside extends global footprint with presentations at medical meetings
- Clearside Biomedical Reports Positive Q3 2024 Results
- Clearside Biomedical reports Q3 EPS (10c), consensus (12c)
- CLSD Earnings Report this Week: Is It a Buy, Ahead of Earnings?